课题基金 / 基金详情

Enzyme Targets, Apoptosis and Purine Metabolism

Enzyme Targets, Apoptosis and Purine Metabolism
酶靶标、细胞凋亡和嘌呤代谢
批准号:
6333917
负责人:
Vincent Jo Davisson
金额:
$14.85万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-04-01 至 2003-03-31

项目摘要

项目成果

Vincent Jo Davisson的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (provided by applicant) Many drugs from nature present complex molecular architectures that result in varied degrees of specific interactions with cellular targets. The rational selection and implementation of new cancer therapies would be improved if a basis for assessing all the drug target interactions were available. This proposal will address the importance of multiple drug targets for the ansamycin class of antitumor agents. Our efforts will focus on the molecular target(s) for the experimental breast cancer drug l7-allylamino-17- demethoxygeldanamycin (17-AAG). The benzoquinoid ansamycins geldanamycin (GA) and herbimycin A and the nonapolyketide radicicol have been investigated for their antiproliferative activity showing both cytostatic and cytotoxic activities. Recent studies predict the mode of action for the cytotoxicity is associated with inhibition of the cellular chaperone Hsp90 or its homolog Grp94. This proposal challenges the assumptions that Hsp90 is a primary mode for induction of tumor cell death by GA. We have recently identified a high-affinity binding site for the drug geldanamycin on an enzyme in the de novo purine biosynthetic pathway called ADE2. A thorough analysis of this interaction in tumor cells and its consequences for drug action will provide the scientific basis for using this information in future applications of this drug class. A detailed biochemical characterization of the human ADE2 protein from tumor cells and an investigation of the molecular details dictating its inhibition by GA are proposed. These studies will assess if ADE2 is a suitable target for cancer chemotherapy and if purine depletion is a critical step in the induction of apoptosis. The studies constitute a biorational approach toward a new perspective on targets for anticancer drugs in de novo purine metabolism. A mechanistic understanding of the biochemical role and regulation of the human ADE2 protein in tumor cells will be a fundamental basis for this analysis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pharmaceutical Sciences Core
  • 批准号:
    9981040
  • 项目类别:
  • 资助金额:
    $41.02万
  • 财政年份:
    2019
  • 负责人:
    Vincent Jo Davisson
  • 依托单位:
Pharmaceutical Sciences Core
  • 批准号:
    10671664
  • 项目类别:
  • 资助金额:
    $36.67万
  • 财政年份:
    2019
  • 负责人:
    Vincent Jo Davisson
  • 依托单位:
Pharmaceutical Sciences Core
  • 批准号:
    10426366
  • 项目类别:
  • 资助金额:
    $53.81万
  • 财政年份:
    2019
  • 负责人:
    Vincent Jo Davisson
  • 依托单位:
Pharmaceutical Sciences Core
  • 批准号:
    10241497
  • 项目类别:
  • 资助金额:
    $36.42万
  • 财政年份:
    2019
  • 负责人:
    Vincent Jo Davisson
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: